Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer

Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.

Inclusion Criteria:

Some of the requirements to be in this study are:

• Patient must be at least 18 years old.
• Patient must have been diagnosed with non-small cell lung cancer.
• Patient must be able to visit the doctor's office once a week.
• Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.
• Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.

Exclusion Criteria:

Patients cannot participate in this study for any of the following reasons:

• Patient has previously had chemotherapy.
• Patient has previously had thoracic radiation therapy.
• Patient has received treatment within the last 30 days with a drug that has not received approval by Health Canada for any indication at the time of study entry.
• Female patient is pregnant or breast-feeding.
• Patient is unsuitable to participate in the study in the opinion of the investigator.
• Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.